Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology IV1 Apr 2018PD65-10 PRLZ INCREASES PROSTATE CANCER DOCETAXEL RESISTANCE BY INHIBITING LKB1/AMPK-MEDIATED AUTOPHAGY Jin Zeng, Wei Liu, Yizeng Fan, Dalin He, and Lei Li Jin ZengJin Zeng More articles by this author , Wei LiuWei Liu More articles by this author , Yizeng FanYizeng Fan More articles by this author , Dalin HeDalin He More articles by this author , and Lei LiLei Li More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2994AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Docetaxel-mediated chemotherapy is the first-line standard approach and has been determined to show a survival advantage for metastatic castration-resistant prostate cancer (mCRPC) patients. However, a substantial proportion of patients eventually becomes refractory due to drug resistance. The detailed mechanisms remain unclear. We have previously reported that Prostate Leucine Zipper (PrLZ), a specific oncogene of prostate cancer (PCa), promotes PCa cell growth at the castration-resistant stage, thus suggesting a vital role of PrLZ in the progression of CRPC. In this study, we aimed to investigate the role of PrLZ in docetaxel resistance in PCa, focusing on PrLZ-regulating autophagy pathway. METHODS Human PCa PC3, LNCaP and C4-2 cell lines were used as the model system in vitro and PCa xenografts and PrLZ-knockout mice were used as the model system in vivo. Docetaxel-induced cell death and apoptosis in PCa were determined by MTT and flow cytometry assay. The effects of PrLZ on autophagy were determined by LC3 conversion, LC3 turnover, and LC3-GFP-RFP puncta assay. The role of PrLZ in the regulation of autophagy and liver kinase B1/AMP-activated protein kinase (LKB1/AMPK) signaling pathway was analyzed using immunoblotting, immunoprecipitation, siRNA silencing and plasmid overexpression. RESULTS PrLZ increased docetaxel-mediated drug resistance in PCa both in vitro and in vivo. PrLZ was involved in both glucose starvation and docetaxel-induced autophagy. Mechanistic dissection revealed that PrLZ interacted with LKB1 and further inhibited the activation of LKB1/AMPK signals, which negatively contributed to the induction of autophagy. Moreover, PrLZ/LKB1-mediated autophagy conferred resistance to docetaxel-induced cell death and apoptosis both in vitro and in vivo. CONCLUSIONS These findings identify a novel role of PrLZ in autophagy manipulation and provide new insight into docetaxel chemoresistance in PCa, suggesting a new strategy for treating mCRPC by targeting this newly identified signaling pathway. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1228-e1229 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jin Zeng More articles by this author Wei Liu More articles by this author Yizeng Fan More articles by this author Dalin He More articles by this author Lei Li More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Long Non-Coding RNA PCDRlnc1 Confers Docetaxel Resistance in Prostate Cancer by Promoting Autophagy

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer

PrLZ Increases Prostate Cancer Docetaxel Resistance by Inhibiting LKB1/AMPK-mediated Autophagy.

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

Long Noncoding Rna Ror Regulates Chemoresistance In Docetaxel-Resistant Lung Adenocarcinoma Cells Via Epithelial Mesenchymal Transition Pathway

LncRNA ERVH48-1 Contributes to the Drug Resistance of Prostate Cancer and Proliferation through Sponging of miR-4784 to the Activation of the Wnt/β-Catenin Pathway

TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling

PD65-10 PRLZ INCREASES PROSTATE CANCER DOCETAXEL RESISTANCE BY INHIBITING LKB1/AMPK-MEDIATED AUTOPHAGY

Identification of Biomarkers, Pathways and Potential Therapeutic Target for Docetaxel Resistant Prostate Cancer

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

RBPJ Contributes to Acquired Docetaxel Resistance in Prostate Cancer Cells

Circcyp24a1 Promotes Docetaxel Resistance in Prostate Cancer by Upregulating ALDH1A3

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway

Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 As a Regulator of Docetaxel Resistance in Prostate Cancer Cells

High Expression of Ladinin-1 (LAD1) Predicts Adverse Outcomes: a New Candidate Docetaxel Resistance Gene for Prostatic Cancer (Pca).

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate Cancer

Long Noncoding RNA CCAT1 Acts As an Oncogene and Promotes Chemoresistance in Docetaxel-Resistant Lung Adenocarcinoma Cells.

Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells

MiR-138–5p Inhibits Prostate Cancer Cell Proliferation and Chemoresistance by Targeting APOBEC3B